Abstracts Archive - Page 1183 of 2425 - ACR Meeting Abstracts

Abstract Number: 2678 • 2018 ACR/ARHP Annual Meeting
Integrated Safety Profile of Atacicept from All Clinical Studies to Date
Caroline Gordon^1,2, Roberto Bassi³, Peter Chang⁴, Amy H. Kao³, David Jayne⁵, David Wofsy⁶, Victor Ona³ and Patricia Fleuranceau-Morel³, ¹Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ²University of Birmingham, Birmingham, United Kingdom, ³EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁴EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), BIllerica, MA, ⁵Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ⁶Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: We conducted an integrated analysis of pooled safety data from all 17 atacicept clinical studies to date, across multiple indications, to further define atacicept’s…
Abstract Number: 2679 • 2018 ACR/ARHP Annual Meeting
Glucocorticoids Withdrawal in Systemic Lupus Erythematosus: Are Remission and Low Disease Activity Reliable Starting Points for Stopping Therapy? a Real-Life Experience
Viola Signorini, Chiara Tani, Elena Elefante, Chiara Stagnaro, Linda Carli and Marta Mosca, Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: Glucocorticoids (GC) are a cornerstone of the treatment of Systemic Lupus Erythematosus (SLE); however, a significant organ damage is associated with long-term GC use…
Abstract Number: 2680 • 2018 ACR/ARHP Annual Meeting
Activation Towards Health Self-Management in Patients with Systemic Lupus Erythematosus
Paul R. Fortin¹, Carolyn Neville², Anne-Sophie Julien³, Murray Rochon⁴, Davy Eng⁵, Christine A. Peschken⁶, Evelyne Vinet⁷, Marie Hudson⁸, Doug Smith⁹, Mark Matsos¹⁰, Janet E. Pope¹¹, Ann E. Clarke¹², Stephanie Keeling¹³, J. Antonio Avina-Zubieta¹⁴ and Deborah Da Costa¹⁵, ¹Medicine, CHU de Québec - Université Laval, Québec, QC, Canada, ²Department of Medicine, McGill University Health Center, Montreal, QC, Canada, ³CHU de Québec - Université Laval, Quebec City, QC, Canada, ⁴Jack Digital, Toronto, ON, Canada, ⁵Centre de recherche du CHU de Québec - Université Laval - Axe maladies infectieuses et immunitaires, CHU de Québec - Université Laval, Quebec, QC, Canada, ⁶RR 149G, University of Manitoba, Winnipeg, MB, Canada, ⁷Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁸Division of Rheumatology, Jewish General Hospital, Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁹Division of Rheumatology, Department of Medicine, The Ottawa Hospital - University of Ottawa, Ottawa, ON, Canada, ¹⁰Medicine, McMaster University, Hamilton, ON, Canada, ¹¹Department of Medicine, University of Western Ontario, London, ON, Canada, ¹²Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹³Department of Medicine, University of Alberta, University of Alberta, Edmonton, AB, Canada, ¹⁴Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ¹⁵Medicine, McGill University, Montreal, QC, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with fluctuating levels of disease activity. Control of disease activity is associated with better outcomes…
Abstract Number: 2681 • 2018 ACR/ARHP Annual Meeting
Lupus Primary Care Management Practices
Karin Tse and R. Paola Daly, Lupus Foundation of America, Washington, DC
Background/Purpose: Due to the systemic nature of lupus, individuals may interact with a diverse health care team when experiencing lupus symptoms and before receiving a…
Abstract Number: 2682 • 2018 ACR/ARHP Annual Meeting
Novel Antibody Against Commensal Bacterial Antigen in Prediction of the Response of Rituximab in Systemic Lupus Erythematosus
Yu-Min Kuo^1,2, Jenhao Chen³, Jean-san Chia⁴, Chiau-jing Jung⁵ and Song-Chou Hsieh⁶, ¹Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan, Taipei, Taiwan, ²Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ³Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, National Taiwan University Hospital,Yunlin branch, Yunlin County, Taiwan, ⁴Graduate Institute of Immunology, National Taiwan University College of Medicine, Taipei, Taiwan, ⁵Department of Microbiology and Immunology, School of Medicine,, College of Medicine, Taipei Medical University, Taipei, Taiwan, ⁶National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Streptoccocal infections can cause rheumatic fever sharing clinical presentations similar to SLE. Whether oral commensal streptococci could induce cross-reactive and pathogenic antibodies remained unknown.…
Abstract Number: 2683 • 2018 ACR/ARHP Annual Meeting
Selective Expansion and Targeting of FoxP3+CD127lo Regulatory T Cells By Low-Dose IL-2 Therapy in Active SLE
Jens Humrich¹, Caroline von Spee-Mayer², Philipp Enghard³, Angelika Rose⁴, Elise Siegert⁵, Tobias Alexander⁵, Falk Hiepe⁶, Gerd R. Burmester⁷ and Gabriela Riemekasten⁸, ¹Department of Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany, ²Immunology, University Hospital Freiburg, Freiburg, Germany, ³Department of Nephrology, Charité – University Medicine Berlin, Berlin, Germany, ⁴Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, ⁵Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ⁶Rheumatology, Charité – University Medicine Berlin, Berlin, Germany, ⁷Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ⁸Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany
Background/Purpose: Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies…
Abstract Number: 2684 • 2018 ACR/ARHP Annual Meeting
Type I IFN, TLR7, MHC Class I, B Cell and OX40 Pathways Suppressed By Anifrolumab (anti-type I IFN receptor) in Moderate to Severe SLE Patients
Katie Streicher¹, Jixin Wang¹, Philip Z. Brohawn², Brandon W. Higgs², Raj Tummala³ and Koustubh Ranade⁴, ¹Translational Medicine, MedImmune, Gaithersburg, MD, ²MedImmune LLC, Gaithersburg, MD, ³MedImmune, Gaithersburg, MD, ⁴Translational Medicine, MedImmune LLC, Gaithersburg, MD
Background/Purpose: Type I interferon has been identified as one of the central mediators in the pathogenesis of SLE, such that patients are characterized by activation…
Abstract Number: 2685 • 2018 ACR/ARHP Annual Meeting
Interferon-Inducible Gene Expression Kit As a Potential Diagnostic Test for Anifrolumab: Analytical Validation for Use in Clinical Trials
Philip Z. Brohawn¹, Brandon W. Higgs¹, Sabina Patel², Adrian Moody³, Peter Cooper³ and Koustubh Ranade⁴, ¹MedImmune LLC, Gaithersburg, MD, ²AstraZeneca, Cambridge, United Kingdom, ³QIAGEN Manchester Ltd., Manchester, United Kingdom, ⁴Translational Medicine, MedImmune LLC, Gaithersburg, MD
Background/Purpose: Anifrolumab is a fully human monoclonal antibody that binds to the type I interferon (IFN) receptor. Its efficacy and safety in the treatment of…
Abstract Number: 2686 • 2018 ACR/ARHP Annual Meeting
Podocyte Foot Process Width Is a Prediction Marker for Complete Renal Remission at 6 and 12 Months after Induction Therapy in Lupus Nephritis
Kunihiro Ichinose¹, Mineaki Kitamura², Shuntaro Sato³, Keita Fujikawa⁴, Yoshiro Horai⁵, Naoki Matsuoka⁶, Masahiko Tsuboi⁶, Fumiaki Nonaka⁷, Masataka Umeda¹, Tomohiro Koga⁸, Takashi Igawa⁸, Tomoya Nishino² and Atsushi Kawakami⁸, ¹Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Nephrology, Nagasaki University Hospital, Nagasaki, Japan, ³Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan, ⁴Japan Community Health care Organization Isahaya General Hospital, Nagasaki, Japan, ⁵Department of Rheumatology, Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan, ⁶Nagasaki Medical Hospital of Rheumatology, Nagasaki, Japan, ⁷Department of Internal Medicine, Sasebo City General Hospital, Sasebo, Japan, ⁸Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Background/Purpose: Lupus nephritis (LN) is a most important predictor of morbidity and mortality in patients with systemic lupus erythematosus (SLE).Histopathology samples from patients with LN…
Abstract Number: 2687 • 2018 ACR/ARHP Annual Meeting
Patient-Level Evaluation of Components of the American College of Rheumatology Combined Response Index in Systemic Sclerosis (CRISS) Using Patient-Reported Anchors
Vivek Nagaraja¹, John Powers², Celia J. F. Lin³, Benjamin Brennan⁴, Veronica J. Berrocal⁵ and Dinesh Khanna¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²University of Maryland School of Medicine, Rockville, MD, ³Genentech, Inc., South San Francisco, CA, ⁴School of Public Health, University of Michigan, Ann Arbor, MI, ⁵Div of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Treatment benefit is demonstrated by evidence that interventions have positive impacts on how patients feel, function, and/or survive (FDA Guidance, 21CFR314.510). The ACR CRISS,…
Abstract Number: 2688 • 2018 ACR/ARHP Annual Meeting
Increased Serum Uric Acid Levels Are Associated with a Higher Risk of Digital Ulcers in Patients with Systemic Sclerosis
Han-Na Lee¹, Seung-Geun Lee¹, Eunsung Kim¹, JungHee Koh¹, Yun-Kyung Kim², Ho-Jae Kim² and Geun-Tae Kim³, ¹Division of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea, Republic of (South), ³Kosin University College of Medicine, Busan, Korea, Republic of (South)
Background/Purpose: Endothelial cell dysfunction and/or injury are considered critical early events in the pathogenesis of vasculopathy in patients with systemic sclerosis (SSc). Hyperuricemia is known…
Abstract Number: 2689 • 2018 ACR/ARHP Annual Meeting
Association between Small Vessel Disease and Arterial Stiffness in Systemic Sclerosis
Stergios Soulaidopoulos¹, Eleni Pagkopoulou¹, Eva Triantafyllidou¹, Niki Katsiki², George D. Kitas^3,4, Asterios Karagiannis², Alexandros Garyfallos¹ and Theodoros Dimitroulas¹, ¹Fourth Department of Internal Medicine, Hippokration University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, ²Second Department of Propaedeutic Internal Medicine, Hippokration University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, ³Department of Rheumatology, Dudley Group of Hospitals, NS Foundation Trust, Dudley, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom
Background/Purpose: Microangiopathy predominates in the pathophysiology of Systemic Sclerosis (SSc). However, large vessel involvement leading to higher risk for cardiovascular disease in SSc remains unclear.…
Abstract Number: 2690 • 2018 ACR/ARHP Annual Meeting
Potential Markers of Skin Involvement in Systemic Sclerosis
Radim Becvar¹, Hana Storkanova², Barbora Sumova¹, Maja Spiritovic¹, Sabina Oreska², Ladislav Šenolt¹ and Michal Tomcik², ¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ²Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Skin fibrosis is a hallmark of systemic sclerosis (SSc). There are no widely accepted biomarkers of skin involvement in this condition. Several serum or…
Abstract Number: 2691 • 2018 ACR/ARHP Annual Meeting
Increased Plasma Angiopoietin-2 in Systemic Sclerosis: Potential for Use As a Biomarker of Vasculopathy and Fibrosis
Victoria Flower^1,2, Shaney Barratt^3,4, Darren Hart⁵, Amanda MacKenzie², Jacqueline Shipley⁵, Stephen Ward² and John Pauling^1,2, ¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trusts, Bath, United Kingdom, ²Centre for Therapeutic Innovations & Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ³Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom, ⁴North Bristol NHS Trust, Bristol, United Kingdom, ⁵Clinical Measurement Department, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trusts, Bath, United Kingdom
Background/Purpose: Angiogenic pathways are likely to contribute to pathogenesis of both vasculopathy and fibrosis in Systemic sclerosis (SSc). The angiogenic actions of Angiopoietins (pro-angiogenic Ang1…
Abstract Number: 2692 • 2018 ACR/ARHP Annual Meeting
High Frequency Ultrasound As a Novel Approach to Quantifying the Digital Microangiopathy of Systemic Sclerosis
Victoria Flower^1,2, Shaney Barratt^3,4, Darren Hart⁵, Amanda MacKenzie², Jacqueline Shipley⁵, Stephen Ward² and John Pauling^1,2, ¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trusts, Bath, United Kingdom, ²Centre for Therapeutic Innovations & Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ³North Bristol NHS Trust, Bristol, United Kingdom, ⁴Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom, ⁵Clinical Measurement Department, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trusts, Bath, United Kingdom
Background/Purpose: Structural and functional vascular abnormalities occur in Systemic Sclerosis (SSc). We report on the use of High Frequency Ultrasound (HFUS) with Superb Microvascular Imaging…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].